Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
Celecoxib and LLW-3-6 Reduce Survival of Human Glioma Cells Independently and Synergistically with Sulfasalazine.
复制标题
DOI：
--
复制
发表时间：
2015-12
影响因子：
2
通讯作者：
T. Yerokun;Leyte L. Winfield
中科院分区：
文献类型：
--
作者：
T. Yerokun;Leyte L. Winfield
神经胶质瘤是最常见的中枢神经系统肿瘤之一。塞来昔布已成功用于治疗几种类型的癌症，包括神经胶质瘤。本研究检测了塞来昔布及其苯并咪唑类似物LLW-3-6与柳氮磺胺吡啶联合治疗对人脑胶质瘤LN 18细胞的抗增殖作用。在48小时处理时，在存在最大测试浓度（40 μM）的塞来昔布或LLW-3-6的情况下，胶质瘤细胞保持60%的活力。在非致死剂量（50 μM）的柳氮磺胺吡啶和塞来昔布或LLW-3-6（以不同浓度给药）共同处理胶质瘤细胞后，细胞活力的抑制作用得到改善。在联合治疗中减少细胞生长所需的分子浓度显著低于单独施用任一分子时所需的浓度。基于计算值，LLW-3-6具有与塞来昔布相比可提高生物利用度的理化特性。
Gliomas are among the most commonly diagnosed central nervous system tumors. Celecoxib has been utilized with success in the treatment of several types of cancer, including gliomas. The present study examined the antiproliferative effects of celecoxib and its benzimidazole-based analog, LLW-3-6, when used as co-treatment with sulfasalazine against human glioma LN18 cells. At 48-h treatment, the glioma cells maintained 60% viability in the presence of celecoxib or LLW-3-6 at the maximum concentration tested (40 μM). Co-treatment of glioma cells under a non-lethal dose (50 μM) of sulfasalazine and either celecoxib or LLW-3-6 (administered at different concentrations) resulted in improved inhibition of cell viability. The concentration of the molecules required to reduce cell growth in the combined treatment was significantly less than that needed when either molecule was administered independently. Based on computational values, LLW-3-6 has physiochemical characteristics that should allow for improved bioavailability in comparison to that of celecoxib.